
Heartflow's AI Plaque Analysis software leads to significant improvements in cholesterol management and cardiac risk reduction in coronary artery disease patients.
Key Details
- 1DECIDE Registry, the largest prospective study of its kind, enrolled ~20,000 CAD patients at 30+ US clinical sites.
- 2Heartflow AI Plaque Analysis prompted treatment changes in over 50% of patients versus CCTA alone.
- 3Patients managed using the software saw mean LDL cholesterol reductions of 18.7 mg/dL.
- 4A 15% estimated reduction in cardiac event risk was observed for these patients.
- 5Significant management changes occurred even in patients with no calcified plaque.
- 6The AI provides individualized risk insights by quantifying and characterizing all plaque types, including non-calcified, soft plaques.
Why It Matters

Source
Cardiovascular Business
Related News

LLMs Demonstrate Strong Potential in Interventional Radiology Patient Education
DeepSeek-V3 and ChatGPT-4o excelled in accurately answering patient questions about interventional radiology procedures, suggesting LLMs' growing role in clinical communication.

Stanford Team Introduces Real-Time AI Safety Monitoring for Radiology
Stanford researchers introduced an ensemble monitoring model to provide real-time confidence assessments for FDA-cleared radiology AI tools.

Harrison.ai Receives FDA Breakthrough Status for Imaging AI Device
Harrison.ai has been awarded three FDA breakthrough device designations for its imaging AI solutions, including a tool for obstructive hydrocephalus triage.